Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 3/20 | 0.65 |
| ▸ | LMNA | P02545 | 3/20 | 0.60 |
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.59 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | BLM | P54132 | 1/20 | 0.59 |
| ▸ | PARP1 | P09874 | 1/20 | 0.59 |
| ▸ | GRIN2D | O15399 | 3/20 | 0.56 |
| ▸ | GRIN3B | O60391 | 3/20 | 0.56 |
| ▸ | GRIN1 | Q05586 | 3/20 | 0.56 |
| ▸ | GRIN2A | Q12879 | 3/20 | 0.56 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.56 |
| ▸ | GRIN2C | Q14957 | 3/20 | 0.56 |
| ▸ | GRIN3A | Q8TCU5 | 3/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.54 |
| ▸ | CA12 | O43570 | 1/20 | 0.53 |
| ▸ | CA9 | Q16790 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9007825 | 0.86 | DAO (0.65) | DAOLMNAHPGDMEN1KMT2A | |
| SCHEMBL9086944 | 0.79 | LMNA (0.70) | DAOLMNAHPGDMEN1KMT2A | |
| SCHEMBL7811758 | 0.79 | LMNA (0.60) | DAOLMNAHPGDMEN1KMT2A | |
| SCHEMBL9007836 | 0.79 | METAP2 (0.49) | DAOLMNAHPGD | |
| SCHEMBL9007832 | 0.79 | DAO (0.65) | DAOLMNAHPGDMEN1KMT2A | |
| SCHEMBL9387738 | 0.79 | DAO (0.65) | DAOLMNAMEN1KMT2AKDM4E | |
| SCHEMBL16767847 | 0.79 | DAO (1.00) | DAOGRIN2DGRIN3BGRIN1GRIN2A | |
| SCHEMBL20693887 | 0.77 | LMNA (0.57) | DAOLMNAHPGDMEN1KMT2A | |
| SCHEMBL2639080 | 0.77 | DAO (0.61) | DAOLMNAHPGDMEN1KMT2A | |
| SCHEMBL8874832 | 0.76 | PARP1 (0.75) | DAOLMNAHPGDMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0517876-B1 | THERAPEUTIC BENZAZEPINE COMPOUNDS | ZENECA LTD (GB) | 1996-10-23 | — | — | EP | claimed |
| US-5446039-A | Treating nervous system and brain disorder, acting as excitatory amino acid antagonist | IMPERIAL CHEMICAL INDUSTRIES, PLC (GB) | 1995-08-29 | — | — | US | claimed |
| US-5254683-A | Neurological disorders | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-10-19 | — | — | US | claimed |
| EP-0517876-A1 | THERAPEUTIC BENZAZEPINE COMPOUNDS. | ICI PLC (GB) | 1992-12-16 | — | — | EP | claimed |
| WO-1992011854-A1 | THERAPEUTIC BENZAZEPINE COMPOUNDS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-07-23 | — | — | WO | claimed |
| US-20170072005-A1 | COMBINATIONS OF NMDAR MODULATING COMPOUNDS | UNIV NORTHWESTERN (US) | 2017-03-16 | — | — | US | disclosed |
| US-20170072005-A1 | COMBINATIONS OF NMDAR MODULATING COMPOUNDS | UNIV NORTHWESTERN (US) | 2017-03-16 | — | — | US | disclosed |
| WO-1998005337-A1 | USE OF GABA AND NMDA RECEPTOR LIGANDS FOR THE TREATMENT OF MIGRAINE HEADACHE | COCENSYS, INC. (US) | 1998-02-12 | — | — | WO | disclosed |
| EP-0517876-B1 | THERAPEUTIC BENZAZEPINE COMPOUNDS | ZENECA LTD (GB) | 1996-10-23 | — | — | EP | disclosed |
| US-5541319-A | REACTING SUBSTITUTED BENZAZEPINE ETHER WITH BORON TRIHALIDE TO FORM HYDROXY GROUP, FORMING SALT WITH BASE IF DESIRED | ZENECA LIMITED (GB) | 1996-07-30 | — | — | US | disclosed |
| US-5446039-A | Treating nervous system and brain disorder, acting as excitatory amino acid antagonist | IMPERIAL CHEMICAL INDUSTRIES, PLC (GB) | 1995-08-29 | — | — | US | disclosed |
| WO-1994007500-A1 | 2,5-DIHYDRO-2,5-DIOXO-1H-AZEPINES AND 2,5-DIHYDRO-2-OXO-1H-AZEPINES AND THE USE THEREOF AS EXCITATORY AMINO ACID AND GLYCINE RECEPTOR ANTAGONISTS | WEBER ECKARD (US) | 1994-04-14 | — | — | WO | disclosed |
| US-5254683-A | Neurological disorders | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1993-10-19 | — | — | US | disclosed |
| EP-0517876-A1 | THERAPEUTIC BENZAZEPINE COMPOUNDS. | ICI PLC (GB) | 1992-12-16 | — | — | EP | disclosed |
| WO-1992011854-A1 | THERAPEUTIC BENZAZEPINE COMPOUNDS | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1992-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170072005-A1 | COMBINATIONS OF NMDAR MODULATING COMPOUNDS | GRIN1, GRIN2A, GRIN3A | DAO 785/4885LMNA 4744/4885HPGD 4026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.